Study summary
An anti-CD38 antibody quickly lowered the antibodies that cause membranous nephropathy
76.9%with at least a 50% drop in anti-PLA2R antibodies
What was tested
Felzartamab, an antibody against CD38 on antibody-making plasma cells, given in 9 infusions over 24 weeks, in high-risk anti-PLA2R-positive membranous nephropathy, including disease that resisted other drugs.
What they found
- Anti-PLA2R antibodies fell by half or more in 76.9%.
- Partial proteinuria remission occurred in 34.6%.
- Infusion reactions and low antibody levels were the main side effects.
What it means
Led to the phase 3 PROMINENT trial against tacrolimus.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.